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INTRODUCTION
In the UK, over 47 000 patients are diagnosed 
with lung cancer each year and the disease 
is the leading cause of cancer mortality, 
accounting for 21% of all UK cancer-related 
deaths.1,2 Though lung cancer survival rates 
in the UK have improved over the last decade, 
they remain less favourable than in other 
Northern and Western European countries, 
partly due to the more advanced stage at 
diagnosis in UK patients.3,4 Missed diagnostic 
opportunities, which can result from 
interactions between patient and healthcare 
practitioner, and health-system factors, may 
contribute to late-stage diagnosis and poor 
cancer outcomes.5,6
Achieving more timely cancer diagnosis 
is a key strategy of the NHS.7 This strategy 
is supported by the National Institute for 
Health and Care Excellence (NICE) cancer 
guidelines, which provide evidence-based 
recommendations to GPs in England, Wales, 
and Northern Ireland on the investigation 
and referral of patients with symptoms of 
possible cancer.8,9 However, few studies have 
assessed how frequently these guidelines 
are followed. With limited evidence on 
guideline concordance, assessing the impact 
of recommendations is challenging.
Previous studies have investigated 
timeliness of diagnostic activities for lung 
cancer that occur after referral from 
primary care, such as waiting times for 
specialist appointments.10–13 However, little 
is known about potential missed diagnostic 
opportunities in primary care when patients 
first present with symptoms. An improved 
understanding of how patients with cancer-
associated features are managed in primary 
care before referral to specialist care could 
help identify missed diagnostic opportunities 
and guide interventions aimed at improving 
the timeliness of cancer diagnosis and 
treatment.5
Chest X-ray was recommended as the 
first-line investigation in patients presenting 
with features of possible lung cancer in 
the 2005 NICE guidelines and the revised 
2015 guidelines.8,9 They recommended that 
chest X-ray is performed within 14 days 
of symptomatic presentation, including 
persistent cough, shortness of breath, or 
weight loss.8,9 This study aimed to examine the 
time to chest X-ray in symptomatic patients 
presenting in English general practice before 
lung cancer diagnosis, and to determine 
what proportion of patients had a chest X-ray 
within the recommended 14-day timeframe. 
In addition, the authors sought to explore 
how time to chest X-ray varied with age, sex, 
smoking status, and deprivation level. 
METHOD
Study design and population
This retrospective cohort study utilised 
routinely collected datasets from NHS 
patients in England. This included primary 
care data from the Clinical Practice 
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Background
National guidelines in England recommend 
prompt chest X-ray (within 14 days) in patients 
presenting in general practice with unexplained 
symptoms of possible lung cancer, including 
persistent cough, shortness of breath, or weight 
loss.
Aim
To examine time to chest X-ray in symptomatic 
patients in English general practice before lung 
cancer diagnosis, and explore demographical 
variation.
Design and setting
Retrospective cohort study using routinely 
collected general practice, cancer registry, and 
imaging data from England.
Method
Patients with lung cancer who presented 
symptomatically in general practice in the year 
pre-diagnosis and who had a pre-diagnostic chest 
X-ray were included. Time from presentation 
to chest X-ray (presentation–test interval) was 
determined and intervals classified based 
on national guideline recommendations as 
concordant (≤14 days) or non-concordant 
(>14 days). Variation in intervals was examined by 
age, sex, smoking status, and deprivation.
Results
In a cohort of 2102 patients with lung cancer, 
the median presentation–test interval was 49 
(interquartile range [IQR] 5–172) days. Of these, 
727 (35%) patients had presentation–test intervals 
of ≤14 days (median 1 [IQR 0–6] day) and 1375 
(65%) had presentation–test intervals of >14 days 
(median 128 [IQR 52–231] days). Intervals were 
longer among patients who smoke (equivalent 
to 63% longer than non-smokers; P<0.001), 
older patients (equivalent to 7% longer for every 
10 years from age 27; P = 0.013), and females 
(equivalent to 12% longer than males; P = 0.016).
Conclusion
In symptomatic primary care patients who 
underwent chest X-ray before lung cancer 
diagnosis, only 35% were tested within the 
timeframe recommended by national guidelines. 
Patients who smoke, older patients, and females 
experienced longer intervals. These findings could 
help guide initiatives aimed at improving timely 
lung cancer diagnosis.
Keywords
clinical practice guideline; diagnostic intervals; 
early diagnosis; lung cancer; chest X-ray.
1  British Journal of General Practice, Online First 2021
KD Arendse, MPhil, MB ChB, research associate; 
FM Walter, MA, MD, FRCGP, reader in primary 
care cancer research; M Pilling, MSc, PhD, senior 
research associate in statistics; Y Zhou, MSc, 
MRCGP, Wellcome Trust primary care doctoral 
fellow; G Funston, BSc, MB BChir, clinical research 
fellow, Primary Care Unit, Department of Public 
Health and Primary Care, University of Cambridge, 
Cambridge. W Hamilton (ORCID: 0000-0003-1611-
1373), MD, FRCP, FRCGP, professor of primary care 
diagnostics, University of Exeter, Exeter.
Address for correspondence
Garth Funston, Primary Care Unit, Department 
of Public Health and Primary Care, Strangeways 
Research Laboratory 2, Worts’ Causeway, 
Cambridge CB1 8RN, UK.
Email: gf272@medschl.cam.ac.uk
Twitter: @funstongarth
Submitted: 25 February 2020; Editor’s response:  
17 May 2020; final acceptance: 17 August 2020.
©The Authors
This is the full-length article (published online 
12 Jan 2021) of an abridged version published in 
print. Cite this version as: Br J Gen Pract 2021; 
DOI: https://doi.org/10.3399/bjgp20X714077
Research Datalink (CPRD), cancer registry 
data from the National Cancer Registration 
and Analysis Service (NCRAS), and imaging 
data from the Hospital Episode Statistics 
Diagnostic Imaging Dataset (HES DID). 
The CPRD consists of anonymised, coded 
data collected from GP records, including 
information on demographics, symptoms, 
and diagnoses. The CPRD contains data 
on some 11 million patients and is broadly 
representative of the UK population.14 
NCRAS data contain information on patients 
diagnosed with cancer including diagnosis 
date, tumour type, and stage. HES DID 
data contain imaging information, including 
test type and imaging dates for patients 
undergoing imaging in NHS hospitals.15,16 
Datasets for this study were linked at patient 
level by NHS digital.16
Patient sample
This research forms part of a broader study 
(protocol number: 17_107R). The cohort for 
the broader study includes patients with 
a code for any of the 11 common cancers 
recorded in CPRD between 1 April 2012 
and 31 December 2015. From this baseline 
cohort, patients were included if they had 
a code for lung cancer in NCRAS. Date of 
diagnosis was taken as the first record of lung 
cancer in NCRAS rather than CPRD because 
NCRAS uses a hierarchical approach for 
determining diagnosis dates.17
Patients were included if they:
• had a new record of primary lung cancer;
• presented with symptoms and/or signs of 
possible lung cancer in the year before; 
diagnosis (Box 1); and
• had a pre-diagnostic chest X-ray after first 
symptomatic presentation.
First presentation
Symptomatic presentations were identified 
from CPRD data using a predeveloped list 
of codes for the lung cancer symptoms and 
signs from the 2005 NICE guidelines.18–20 This 
includes haemoptysis, dyspnoea, weight loss, 
hoarseness, and cough (Box 1).8 As in similar 
studies, first presentation was taken as the 
first recorded symptom or sign of possible 
lung cancer in the year pre-diagnosis.18,19 
Patients without a recorded symptomatic 
presentation in the year pre-diagnosis were 
excluded. The authors also excluded people 
who smoke or ex-smokers aged ≥40 years 
with haemoptysis, and patients with superior 
vena caval obstruction and stridor, as NICE 
guidelines recommend direct specialist 
referral rather than chest X-ray for these 
patients (Box 1).8 The number of recorded 
symptoms and signs on the date of first 
presentation was documented as 1 or >1 for 
analysis.
Chest X-ray
Patients with a pre-diagnostic chest 
X-ray recorded in HES DID after first 
presentation were included. Time from 
first symptomatic presentation to chest 
X-ray, the ‘presentation–test’ interval was 
calculated for each patient (Figure 1). 
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How this fits in 
England’s national cancer referral guidelines 
recommend that patients attending general 
practice with unexplained symptoms possibly 
caused by lung cancer, such as persistent 
cough, shortness of breath, and weight loss, 
have a chest X-ray promptly (within 14 days) 
to aid timely diagnosis. Only 35% of patients 
with lung cancer in this study had a chest 
X-ray within the recommended 14 days; and 
time between attending general practice 
with symptoms and having an X-ray was 
longer among people who smoke, females, 
and older patients. This research highlights 
a potential source of delayed lung cancer 
diagnosis and could inform initiatives aiming 
to achieve earlier diagnosis and improve 
outcomes.
Box 1. National Institute for Health and Care Excellence guidelines 
for referral of suspected cancer (2005)8
Section 1.3: Lung cancer 
Specific recommendations
1.3.2. An urgent referral for a chest X-ray should be made when a patient presents with:
• haemoptysis, or
• any of the following unexplained persistent, that is, lasting >3 weeks, symptoms and signs: chest 
and/or shoulder pain, dyspnoea, weight loss, chest signs, hoarseness, finger clubbing, cervical and/
or supraclavicular lymphadenopathy, cough with or without any of the above, features suggestive of 
metastasis from a lung cancer, for example, in brain, bone, liver, or skin.
1.3.3. An urgent referral should be made for either of the following:
• persistent haemoptysis in smokers or ex-smokers who are aged ≥40 years; or 
• a chest X-ray suggestive of lung cancer (including pleural effusion and slowly resolving consolidation).
1.3.4. Immediate referral should be considered for the following:




The referral timelines used in this guideline are as follows:
• Immediate: an acute admission or referral occurring within a few hours, or even more quickly if necessary.
• Urgent: the patient is seen within the national target for urgent referrals (currently 2 weeks).
Presentation–test intervals of ≤14 days were 
considered guideline concordant, as NICE 
2005 guidelines recommended a chest X-ray 
within 14 days of presentation.8
Demographics
Patients were categorised as ‘smoker’, 
‘ex-smoker’ or ‘non-smoker’ using their 
most recent smoking code before chest 
X-ray (see Supplementary Appendix S1). As 
NICE guidelines made recommendations for 
investigation and referral based on smoking 
status, patients without smoking data were 
excluded.8 Only the year of birth for each 
patient was available. The authors assigned 
all patients the birth date of 1 July. The index 
of multiple deprivation was documented in 
quintiles, 1 being the least and 5 the most 
deprived.
Statistical analysis
The association between presentation–
test interval duration (number of days as 
an integer), and sex, age, smoking, and 
deprivation was investigated. Age and sex 
were evaluated because of their association 
with timeliness in cancer diagnosis in 
previous studies.10,19 Deprivation was 
included because lung cancer mortality 
rates are highest among deprived groups.21,22 
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Figure 1. Evaluated time intervals from presentation 
to diagnosis.
Figure 2. Application of study inclusion criteria. 
CPRD = Clinical Practice Research Datalink. HES 
DID = Hospital Episode Statistics Diagnostic Imaging 
Dataset. NCRAS = National Cancer Registration and 











Chest X-ray >14 days
after presentation
n = 1375
Patients with features of possible
lung cancer recorded in CPRD in the
year pre-diagnosis
n = 2553
Patients with a pre-diagnostic chest
X-ray after symptomatic
presentation recorded in HES DID
n = 2201
Patients qualifying for chest X-ray
investigation for possible lung
cancer in NICE 2005 guidelines
n = 2102
Patients with lung cancer identified
from NCRAS
N = 3645




No features of possible lung cancer
recorded in CPRD in the year pre-diagnosis
n = 1092
Excluded:
No pre-diagnostic chest X-ray in HES DID
n = 352
Excluded:
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Smoking was included because of its 
strong link to respiratory comorbidity and 
its importance in lung cancer aetiology.23,24 
Number of clinical features were accounted 
for at first presentation as multiple features 
are more predictive of lung cancer than 
single features.25
Unadjusted analyses were performed to 
explore the isolated effect of each variable 
and adjusted multivariable regression to 
explore combined effects. Regression model 
diagnostics were examined and assumptions 
were satisfied, that is, negative binomial 
dispersion parameter alpha was significant 
and residual plot was satisfactory. Incidence 
rate ratios (IRR) were calculated to determine 
relative effects of variables on presentation–
test interval duration using negative binomial 
regression. Variables with an IRR >1 were 
interpreted as being associated with more 
days between presentation and chest X-ray, 
which is equivalent to longer intervals. For 
example, an IRR of 1.5 = 50% more days, 
which is equivalent to a 50% longer interval. 
A Cox proportional-hazards model was fitted 
as a sensitivity analysis and gave very similar 
conclusions. 
All data management and analyses were 
conducted using Stata (version 15.1). 
RESULTS
Patient cohort and demographics
A total of 3645 patients had a new lung 
cancer diagnosis during the study period, of 
whom 2553 (70%) presented with features 
of possible lung cancer in the year pre-
diagnosis. Of these, 2201 patients (86%) had a 
pre-diagnostic chest X-ray after presentation. 
A further 99 patients were excluded: 85 (4%) 
qualified for direct specialist referral, two 
had missing deprivation data, and 12 had 
missing smoking data (<1%) (Figure 2). The 
final cohort (n = 2102) had a median age of 
72 years. Of these, 1148 patients (55%) were 
male. The majority were ex-smokers (56%, 
n = 1168) or smokers (37%, n = 785). Patient 
demographics are summarised in Table 1.
Stage and histology
Most patients had a histological (n = 1479, 
70%) or cytological (n = 217, 10%) diagnosis. 
In total, 1472 (70%) had non-small-cell lung 
cancer, 249 (12%) had small-cell lung cancer 
and 381 (18%) were unspecified. Stage was 
documented for 1959 (93%) patients; most 
had stage III (n = 490; 25%) or stage IV 
(n = 1019; 52%) lung cancer (data not shown). 
Time to chest X-ray and guideline 
concordance
The overall median presentation–test 
interval was 49 (interquartile range [IQR] 
5–172) days. A total of 727 (35%) patients 
had a presentation–test interval ≤14 days, 
that is, guideline concordant (median 1 
[IQR 0–6] day). The remaining 1375 (65%) 
patients had a presentation–test interval of 
>14 days (median 128 [IQR 52–231] days), 
that is, guideline non-concordant (Table 1).
Demographic variation in intervals
Median presentation–test intervals are 
displayed by demographics in Table 2. 
Multivariable regression showed longer 
presentation–test intervals among smokers 
than non-smokers (IRR 1.63, 95% confidence 
interval [CI] = 1.29 to 2.05; equivalent to 63% 
longer; P<0.001), older patients (IRR 1.07, 
95% CI = 1.01 to 1.12, for every additional 
10 years from age 27; equivalent to 7% 
longer; P = 0.013) and females (IRR 1.12, 
95% CI = 1.02 to 1.24; equivalent to 12% 
longer than males; P = 0.016). Deprivation 
was weakly associated with presentation–
test intervals, showing longer intervals 
with greater deprivation. Presentation–test 
intervals were longer among patients with 
Table 1. Proportion of NICE-guideline concordant pre-diagnostic 
chest X-rays (≤14 days after presentation) among symptomatic 
patients with lung cancer by sociodemographic factors
 Patients in cohort, n (%)
 Chest X-ray ≤14 days  Chest X-ray >14 days  
 (guideline concordant) (guideline non-concordant) Total, N
All 727 (35) 1375 (65) 2102
Sex
 Male 426 (37) 722 (63) 1148
 Female 301 (32) 653 (68) 954
Age categories, years
 <40 1 (33) 2 (67) 3
 40–49 25 (48) 27 (52) 52
 50–59 85 (35) 156 (65) 241
 60–69 214 (37) 362 (63) 576
 70–79 240 (32) 517 (68) 757
 80–89 142 (34) 279 (66) 421
 ≥90 20 (38) 32 (62) 52
Deprivation quintile
 1 (least deprived) 133 (36) 234 (64) 367
 2 147 (40) 223 (60) 370
 3 141 (33) 280 (67) 421
 4 152 (35) 286 (65) 438
 5 (most deprived) 154 (30) 352 (70) 506
Smoking status   
 Non-smoker 71 (48) 78 (52) 149
 Ex-smoker 396 (34) 772 (66) 1168 
 Smoker 260 (33) 525 (67) 785
Number of features on  
first presentation
 1 692 (35) 1285 (65) 1977
 >1 35 (28) 90 (72) 125
>1 symptom on presentation, though this 
association was weak (IRR 1.20, 95% CI = 1.00 
to 1.43; equivalent to 20% longer; P = 0.052).
DISCUSSION
Summary
In this study, only 35% of patients with lung 
cancer had a pre-diagnostic chest X-ray within 
the NICE-recommended 14-day timeframe 
following symptomatic presentation to 
primary care. Time between symptomatic 
presentation and chest X-ray was longer 
among females, smokers, and older 
patients, reflecting a lower rate of guideline 
concordance in these groups. These findings 
highlight a potential missed opportunity for 
timely lung cancer diagnosis in England and 
could be used to guide interventions aimed 
at improving outcomes, particularly targeting 
sociodemographic disparities in healthcare 
access and quality.
Strengths and limitations
This study’s strengths include the large 
sample size, high proportion of complete 
data, the retrospective cohort design, and 
originality. The reliance on codes to identify 
presentations in CPRD is a limitation because 
information about duration was unavailable. 
The 2005 NICE guidelines recommend chest 
X-ray if patients had ‘persistent’ features, 
that is, ≥3 weeks.8 The authors assumed 
that symptoms and signs recorded within 
CPRD had been present for this time period, 
however, some patients may have been 
symptomatic for <3 weeks, which could 
contribute to an underestimation of guideline 
concordance. 
Some patients had no pre-diagnostic chest 
X-ray in HES DID; the authors were unable to 
identify whether this resulted from no pre-
diagnostic X-ray or no recorded data. The 
cohort was restricted to patients diagnosed 
with lung cancer; patients without lung 
cancer who had symptomatic presentations 
warranting a chest X-ray were not evaluated. 
Therefore, the researchers were unable to 
assess overall concordance with guideline-
recommended X-ray timeframes, only 
concordance in those subsequently 
diagnosed with lung cancer. Nevertheless, 
the group evaluated is the most likely to 
benefit from timely investigation and 
diagnosis. 
The effect of comorbid diseases on 
presentation–test intervals was not 
investigated, but the effect of smoking was 
investigated, which is strongly related to key 
comorbidities including chronic obstructive 
pulmonary disease (COPD). Previous studies 
found that comorbidities are associated 
with longer secondary care intervals in lung 
cancer and longer diagnostic intervals in 
other cancer types.13,26,27 Further research 
investigating the relationship between 
comorbidities and presentation–test 
intervals in lung cancer is needed.
Comparison with existing literature 
A previous study reported no significant 
change in lung cancer diagnostic intervals 
after the introduction of the 2005 NICE 
guidelines, which may in part be explained 
by the low concordance with guideline 
recommendations on chest X-ray 
investigations observed in the present 
study.18 Nicholson et al found that GPs in the 
UK only followed national guidelines when 
investigating possible lung cancer 47% of the 
time, lower than non-UK jurisdictions (58%).28 
In contrast, Baughan et al found a high rate 
(90.9%) of compliance with national referral 
guidelines for any cancer.12 The validity of 
these studies is limited by recall bias and 
missing information as both analysed self-
evaluated accounts of compliance. 
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Table 2. Association between demographics and presentation–test 
intervals using negative binomial regressiona
 Patients in cohort Presentation–test interval, days
 n (%) Median (IQR) IRR (adjusted)b 95% CI (P-value)
Total 2102 (100) 49 (5–172) – –
Constant – – 35.77 23.09 to 55.40 (<0.001)
Sex    
 Male 1148 (55) 41 (4–162) Ref –
 Female 954 (45) 63 (7–182) 1.12 1.02 to 1.24 (0.016)
Age 
 For every additional – – 1.07 1.01 to 1.12 (0.013) 
 10 years from age 27
Deprivation quintile
 1 (least deprived) 367 (17) 43 (4–162) Ref –
 2 370 (18) 37 (3–147) 0.86 0.73 to 1.02 (0.081)
 3 421 (20) 46 (6–173) 1.01 0.86 to 1.18 (0.927)
 4 438 (21) 49 (6–184) 1.03 0.88 to 1.21 (0.704)
 5 (most deprived) 506 (24) 73 (9–184) 1.08 0.93 to 1.25 (0.326)
Smoking status
 Non-smoker 149 (7) 18 (1–85) Ref Ref
 Ex-smoker 1168 (56) 52 (6–173) 1.58 1.26 to 1.99 (<0.001)
 Smoker 785 (37) 55 (6–181) 1.63 1.29 to 2.05 (<0.001)
Number of features on  
first presentation
 1 1977 (94) 48 (5–170) Ref Ref
 >1 125 (6) 91 (10–190) 1.20 1.00 to 1.43 (0.052)
ln (alpha) – – 0.82 0.77 to 0.88
aLikelihood ratio (LR) test of alpha = 0, c2 = 240 000, P<0.001. bVariables included in the adjusted analysis 
include sex, age in years, level of deprivation, smoking status, and number of features at first presentation. 
IQR = interquartile range. IRR = incidence rate ratio. ln (alpha) = natural log of alpha. Alpha is the over-dispersion 
parameter (values >0 indicate the distribution’s variance is greater than its mean).
The low guideline concordance identified 
in the present study is likely to be due 
to interacting patient, clinician, and health 
system factors. Health systems can 
contribute to delays if demand for services 
exceeds available resources, for example, 
lack of imaging equipment and professionals 
to perform tests.5,29 Difficulty accessing 
X-rays from primary care could also extend 
intervals. In one study, 32% of GPs reported 
waiting ≥1 week to obtain a chest X-ray.30 
While such system delays may lengthen 
presentation–test intervals, they are likely 
to affect all groups and therefore do not 
necessarily explain differences in interval 
length between demographic subgroups, for 
example, males and females. Lung cancer 
poses a real diagnostic challenge in general 
practice as patients usually present with 
‘low-risk but not no-risk’ clinical features, 
most frequently cough or dyspnoea, which 
are common in non-malignant conditions.31 
This is demonstrated in the present study 
as only 85 of 2201 (4%) patients presented 
with high-risk presentations warranting 
specialist referral and were therefore 
excluded. Diagnostic difficulty can lead to 
multiple pre-diagnostic consultations and 
potential diagnostic delay, particularly 
among individuals with comorbidities.25,32 
Comorbid disease, most evidently COPD, 
may also mask symptoms of lung cancer 
and lengthen intervals.6,33–35 
Associations between timely lung cancer 
diagnosis in the UK and sociodemographic 
factors have been evaluated in previous 
studies.10,19,36 As in the present study, age 
inequalities in cancer services have been 
previously reported, with evidence of longer 
intervals and lower proportions of urgent 
referrals among older patients.10,12,19,37 
Authors have suggested that this may reflect 
a tendency towards therapeutic nihilism or 
discrimination against older patients, whose 
care is often determined by age rather than 
need, despite cancer being more common 
in this population.12,19,36 Furthermore, 
age-related comorbidities may contribute 
to delays and accessibility issues.19,38 Din 
et al noted longer lung cancer diagnostic 
intervals among females, as observed in 
the present study.19 GP behaviour may be 
influenced by sex, with symptoms treated 
as more serious in males prompting more 
rapid investigation.5,19 GPs may consider the 
higher incidence of lung cancer in males 
(particularly historically) when considering 
whether to request investigations.1 The 
longer time to chest X-ray experienced 
by smokers could result from their 
increased risk of respiratory comorbidity (a 
potential confounding factor).23 In addition, 
stigmatisation of smoking may influence 
patients’ decisions to return for chest X-ray 
after being informed of suspected lung 
cancer.39 The present finding that greater 
deprivation is only weakly associated with 
longer test–diagnostic intervals is in keeping 
with a recent systematic review conducted 
by Forrest et al.36 Though other evidence 
shows that higher deprivation is associated 
with increased lung cancer incidence 
and mortality, its relationship to risk and 
outcomes is complex.21,22 It is thought that 
social class contributes to the differences 
in smoking that drives health inequalities 
between the least and most deprived groups, 
particularly impacting the prevalence of lung 
cancer.40 Accounting for smoking, a potential 
mediating factor, could partly explain why a 
weak association between deprivation and 
interval duration was found in the present 
study. 
Implications for research and practice
It is thought that concordance with NICE 
and other evidence-based guidelines will 
improve timely cancer diagnosis, though 
the supporting evidence for lung cancer is 
lacking.7,18,41–44 Longer time intervals allow 
tumour growth and disease progression and 
thus could contribute to poorer lung cancer 
survival.2,45–47 This suggests that the two-
thirds (65%) of patients with lung cancer who 
did not receive guideline concordant care 
in the present study may have experienced 
a missed diagnostic opportunity, and may 
experience poorer outcomes, including 
reduced survival, as a result. However, 
further research exploring the effect of 
longer presentation–test intervals on stage 
and survival would be needed to confirm this. 
As discussed, the poor overall concordance 
with recommended intervals for chest X-ray 
are unlikely to be due to a single cause 
but rather a range of factors. Given the 
importance of early lung cancer diagnosis, 
further research is needed to identify 
causes for low guideline concordance and to 
address them. The present findings support 
theories that older patients, females, and 
smokers are more likely to experience 
delayed diagnosis and missed diagnostic 
opportunities.19,25,32,35 These findings 
could inform future guidelines, education 
programmes, and early diagnostic initiatives. 
Further research, aimed at understanding 
the mechanisms by which presentation–test 
intervals are prolonged in the patient groups 
identified in this study, could help direct 
strategies aimed at reducing diagnostic 
delay in lung cancer. 
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